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OBJECTIVES AND
BACKGROUND
While attention has focused on coronary blood flow in the culprit artery in acute myocardial
infarction (MI), flow in the nonculprit artery has not been studied widely, in part because it
has been assumed to be normal. We hypothesized that slower flow in culprit arteries, larger
territories infarcted and hemodynamic perturbations may be associated with slow flow in
nonculprit arteries.
METHODS The number of frames for dye to first reach distal landmarks (corrected TIMI [Thrombolysis
in Acute Myocardial Infarction] frame count [CTFC]) were counted in 1,817 nonculprit
arteries from the TIMI 4, 10A, 10B and 14 thrombolytic trials.
RESULTS Nonculprit artery flow was slowed to 30.9 6 15.0 frames at 90 min after thrombolytic
administration, which is 45% slower than normal flow in the absence of acute MI (21 6 3.1,
p , 0.0001). Patients with TIMI grade 3 flow in the culprit artery had faster nonculprit artery
CTFCs than those patients with TIMI grades 0, 1 or 2 flow (29.1 6 13.7, n 5 1,050 vs.
33.3 6 16.1, n 5 752, p , 0.0001). The nonculprit artery CTFC improved between 60 and
90 min (3.3 6 17.9 frames, n 5 432, p 5 0.0001), and improvements were related to
improved culprit artery flow (p 5 0.0005). Correlates of slower nonculprit artery flow
included a pulsatile flow pattern (i.e., systolic flow reversal) in the nonculprit artery (p ,
0.0001) and in the culprit artery (p 5 0.01), a left anterior descending artery culprit artery
location (p , 0.0001), a decreased systolic blood pressure (p 5 0.01), a decreased
ventriculographic cardiac output (p 5 0.02), a decreased double product (p 5 0.0002), a
greater percent diameter stenosis of the nonculprit artery (p 5 0.01) and a greater percent of
the culprit artery bed lying distal to the stenosis (p 5 0.04). Adjunctive percutaneous
transluminal coronary angioplasty (PTCA) of the culprit artery restored a culprit artery
CTFC (30.4 6 22.2) that was similar to that in the nonculprit artery at 90 min (30.2 6 13.5),
but both were slower than normal CTFCs (21 6 3.1, p , 0.0005 for both). If flow in the
nonculprit artery was abnormal (CTFC $ 28 frames) then the CTFC after PTCA in the
culprit artery was 17% slower (p 5 0.01). Patients who died had slower global CTFCs (mean
CTFC for the three arteries) than patients who survived (46.8 6 21.3, n 5 47 vs. 39.4 6
16.7, n 5 1,055, p 5 0.02).
CONCLUSIONS Acute MI slows flow globally, and slower global flow is associated with adverse outcomes.
Relief of the culprit artery stenosis by PTCA restored culprit artery flow to that in the
nonculprit artery, but both were 45% slower than normal flow. (J Am Coll Cardiol 1999;34:
974–82) © 1999 by the American College of Cardiology
The thrombolysis in acute myocardial infarction (TIMI)
flow grade (1) in the culprit artery has been the focus of
angiographic trials in patients with acute myocardial infarc-
tion (MI) (2–7). It has been assumed that flow in nonculprit
arteries is normal (1), and little or no attention has been paid
to global measures of flow in all three coronary arteries.
Recently, we described a new index of coronary blood flow,
the corrected TIMI frame count (CTFC), in which the
number of frames required for contrast material to reach
standardized distal landmarks is counted (8). In our initial
description of the CTFC, we noted, in a relatively small
number of patients (n 5 77), that flow was slowed in
nonculprit arteries compared with patients with normal flow
in the absence of acute MI (25.5 6 9.8 vs. 21 6 3.1, p 5
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0.0001) (8). The goal of the present study was to validate
prospectively this observation in a large number of patients,
and to examine the determinants of slowed flow in noncul-
prit arteries. We hypothesized that there would be an asso-
ciation between flows in culprit and nonculprit arteries, and
in their improvement over time. We also hypothesized that
slow flow would be related to hemodynamic perturbations
in the setting of acute MI, and prospectively collected hemo-
dynamic data to examine this hypothesis. This study also
examines the relationship between an index of global flow (the
average frame count of all three arteries) to clinical outcomes.
METHODS
The data are drawn from four TIMI trials: TIMI 4, 10A,
10B and 14. The TIMI 4 trial was a randomized double-
blind comparison of three thrombolytic regimens in 416 pa-
tients (9): Anistreplase (Eminase or APSAC) versus front-
loaded recombinant tissue plasminogen activator (rt-PA)
(Activase or alteplase) versus combination therapy. The
TIMI 10A trial was a nonrandomized, open-label, dose
escalation study of eight ascending doses of TNK (5, 7.5,
10, 15, 20, 30, 40, 50 mg IV over 5 to 10 s) in 113 patients
(10). TIMI 10B was a randomized trial of 30-, 40- and
50-mg doses of TNK versus front-loaded rt-PA in 853
patients. There were 812 patients available for analysis from
the ongoing TIMI 14 trial comparing abciximab versus
abciximab plus low-dose thrombolytic (either tissue plas-
minogen activator [tPA] or streptokinase). Angiography
was performed at 60, 75 and 90 min after thrombolysis
(8–10). Nitroglycerin (IV or sublingual) was administered
every 15 min if the systolic blood pressure exceeded
110 mm Hg (8–10). Hemodynamic data were collected
prospectively in the TIMI 14 trial. Adverse outcomes were
adjudicated by clinical events committees. The TIMI stud-
ies were approved by each participating center’s Institutional
Review Board, and the trial was conducted according to the
principles of the Declaration of Helsinki.
Angiographic analysis methods. Culprit artery location
was based upon the qualifying electrocardiogram, the pres-
ence of a thrombotic or ulcerated lesion and the presence of
a wall motion abnormality on left ventriculography, when
available. The TIMI flow grade was assessed at the TIMI
Angiographic Core Laboratory as previously defined (1). To
evaluate objectively coronary flow as a continuous variable,
the number of cineframes required for contrast to reach
standardized distal coronary landmarks (the TIMI frame
count) was measured using a frame counter on a cineviewer
and converted to the U.S. standard of 30 frames/s (8,11).
Flow was defined to be abnormal when the CTFC was $28
frames (i.e., outside the 95% confidence interval for flow in
patients without acute MI) (8). Pulsatile flow was defined as
cessation of antegrade contrast motion or frank reversal of
contrast motion during systole. End-diastolic frames of
views that minimized foreshortening were chosen for quan-
titative coronary arteriography of the culprit lesion using a
previously described and validated automated edge detec-
tion algorithm (12). Nonculprit lesions were analyzed using
digital calipers (13–15). Wall motion abnormality was
assessed in each region of the heart: anterobasal, anterolat-
eral, apical, inferior and posterobasal. Each wall segment
was classified as either normal, hypokinetic, akinetic or
dyskinetic. Post-assessment, the non-infarct-related artery
was matched with the corresponding wall region to deter-
mine wall motion abnormality. In left anterior descending
artery (LAD) nonculprit arteries, the corresponding wall
regions for determining abnormality were the anterobasal,
anterolateral and apical regions. In left circumflex noncul-
prit arteries, the corresponding wall regions for determining
abnormality were the anterolateral and inferior regions. In
right coronary artery (RCA) nonculprit arteries, the corre-
sponding wall regions for determining abnormality were the
posterobasal and inferior regions.
Statistical analysis. All analyses were performed using
Stata Statistical Software (Stata Corp., College Station,
Texas). All continuous variable values are reported as the
mean 6 SD. The Student t test and analysis of variance
(ANOVA) with a Bonferroni correction were used in the
analysis of normally distributed continuous variables. A
Wilcoxon rank-sum test was used for variables that were not
normally distributed. Chi-square tests were used to assess
categorical variables when appropriate. A p value of ,0.10
was required for retention in multiple linear and multiple
logistic regression models. Patients were randomized into
two random cohorts, and the univariate and multivariate
correlates were validated independently in the two cohorts.
RESULTS
Baseline characteristics can be found in Table 1. The CTFC
for nonculprit arteries at 90 min after thrombolytic admin-
istration was unimodally distributed with a single peak and
a long tail, similar to previously published data for the
CTFC in culprit arteries (Fig. 1) (8).
Abbreviations and Acronyms
ANOVA 5 analysis of variance
CHF 5 congestive heart failure
CTFC 5 corrected TIMI frame count
EF 5 ejection fraction
LAD 5 left anterior descending artery
LCx 5 left circumflex artery
MI 5 myocardial infarction
MRI 5 magnetic resonance imaging
PTCA 5 percutaneous transluminal coronary
angioplasty
RCA 5 right coronary artery
rt-PA 5 recombinant tissue plasminogen activator
TIMI 5 Thrombolysis in Acute Myocardial Infarction
tPA 5 tissue plasminogen activator
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Relation between culprit and nonculprit flow at 90 min
after thrombolysis. In the TIMI 10A, 10B and 14 trials,
the CTFC in nonculprit arteries was elevated to 31.1 6
15.1 (n 5 1,740, p , 0.0001 vs. normal flow), prospectively
validating the results initially observed in TIMI 4 (8).
Taking all trials together, nonculprit artery flow was slowed
to 30.9 6 15 frames at 90 min (n 5 1,817), which is 45%
slower than the normal value of 21 6 3.1 (n 5 78) reported
for flow in the absence of acute MI (p , 0.0001) (8).
Nonculprit CTFCs were slower than culprit CTFCs in 27%
of patients (n 5 387/1,441) whose nonculprit arteries had
lesions ,50% diameter stenosis. We prospectively validated
the benchmark of 21 frames by assessing the CTFC in the
absence of acute coronary syndromes and found the CTFC
to be 21.3 6 6 (n 5 102). Taken together, in all arteries
with normal flow in the absence of acute MI, the normal
CTFC was 21.2 6 4.9 (n 5 180).
Slower culprit artery flow was associated with slower
nonculprit artery flow (r 5 0.24, p , 0.0001), and culprit
arteries that did not achieve TIMI 3 flow or a normal
CTFC (,28 frames) had slower nonculprit artery flow (p ,
0.0001) (Tables 2 and 3). When the LAD was the culprit
artery, flow in the nonculprit artery was significantly slower
than when either the left circumflex artery (LCx) or the
RCA were the culprit artery (p , 0.0001) (Fig. 2). Pulsatile
flow in the culprit artery was associated with an increased
incidence of pulsatile flow in nonculprit arteries (p ,
0.001), as well as slower nonculprit flow (p 5 0.01) (Table
4). A greater reference diameter of the culprit artery (p ,
0.0001) and a greater percent of the culprit artery bed (i.e.,
length of all distal branches ,1.5 mm in diameter) lying
distal to the culprit stenosis (p 5 0.04) were both associated
with slower nonculprit artery flow (Table 3).
Nonculprit artery predictors of nonculprit artery flow.
The presence of an obstructive lesion .50% by visual
estimation in the nonculprit artery did not significantly
impact the CTFC (30.5 6 14.2, n 5 1,165 without lesion
vs. 31.8 6 16.4; n 5 633 with at least one lesion, p 5 NS).
In an analysis confined to nonculprit arteries with an
obstructive lesion .50% by visual estimation, tighter non-
culprit artery minimum lumen diameters and percent diam-
eter stenoses were associated with slower nonculprit artery
flow (Table 3, p 5 0.01). Nonculprit artery flow was slower
when the nonculprit artery had a pulsatile flow pattern (p ,
Table 1. Baseline Characteristics of Patients with
Noninfarct-related Artery
Characteristic
Age (years) 60.1 6 11.9 (n 5 612)
Gender (% male) 77.1% (n 5 471/611)
Height (cm) 171.3 (n 5 542)
Weight (kg) 79.7 (n 5 543)
Race (% white) 73.4% (n 5 448/610)
History of myocardial
infarction
14.0% (n 5 85/607)
Smoker at admission (%) 46.0% (n 5 280/609)
History of congestive
heart failure (%)
2.8% (n 5 16/563)
History of hypertension (%) 37.7% (n 5 226/600)
History of diabetes (%) 14.1% (n 5 85/604)
Systolic blood pressure
(mm Hg)*
134.9 6 21.9 (n 5 610)
Diastolic blood pressure
(mm Hg)*
79.8 6 14.8 (n 5 606)
Pulse (beats/min)* 77.1 6 17.5 (n 5 609)
* Blood pressure and pulse on admission were available in TIMI 4, 10A and 10B.
Blood pressure and pulse in TIMI 14 were at the 90-min catheterization, and are not
included in this table.
Figure 1. Distribution of the CTFC in nonculprit arteries at 90 min after thrombolytic administration. Nonculprit CTFC was unimodally
distributed with a single peak and a long tail, similar to previously published data for the CTFC in culprit arteries (8).
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0.0001 in two cohorts), and when the culprit artery was not
collateralized (p 5 0.01) (Table 2).
Hemodynamic correlates of nonculprit artery flow. He-
modynamic data were collected and analyzed prospectively
in the TIMI 14 trial. Lower systolic (p 5 0.01, n 5 339),
mean arterial blood pressures (p 5 0.04, n 5 248) and heart
rates (p 5 0.04, n 5 280) were associated with slower
nonculprit artery flow. In 90 patients, a reduced ventricu-
lographic cardiac output (calculated by multiplying heart
rate and stroke volume) was associated with slower noncul-
prit artery flow (p 5 0.02), as was a decreased pressure-rate
product (calculated by multiplying systolic blood pressure
and heart rate, p 5 0.0002, n 5 268) and a narrower pulse
pressure (p 5 0.001, n 5 338) (Table 3). Neither the
pulmonary capillary wedge pressure nor the left ventricular
end diastolic pressure achieved statistical significance.
Wall motion abnormalities within the distribution of the
nonculprit artery. Patients with abnormal nonculprit ar-
tery flow (i.e., a CTFC $ 28) had a higher incidence of
regional wall motion abnormalities within the distribution
of the nonculprit artery (p , 0.001, Fig. 3). Likewise, when
the analysis was restricted to patients without a prior MI,
similar findings were observed (p 5 0.038).
Changes in nonculprit artery CTFC over time. In both
unpaired and paired analyses, flow in nonculprit arteries
improved between 60 and 90 min after thrombolysis (Fig.
4). There were greater improvements in nonculprit artery
flow when the culprit artery flow also improved (7.4 vs. 1.0
frames, p , 0.0001; Fig. 5).
Relationship between the 90-min CTFC in nonculprit
arteries and the culprit artery CTFC after angioplasty.
Slower flow in the culprit artery after relief of the residual
stenosis by adjunctive angioplasty was associated with
slower 90-min nonculprit artery flow (p 5 0.02). Indeed,
post-percutaneous transluminal coronary angioplasty
(PTCA) flow was 17% slower if the associated nonculprit
artery flow was abnormal at 90 min (i.e., $ 28 frames)
(32.8 6 21.8 vs. 28 6 22.4, p 5 0.01). In a paired analysis,
PTCA of the residual stenosis in the culprit artery restored
a CTFC that was similar to that in the nonculprit artery at
90 min in a paired analysis (30.4 6 22.2 vs. 30.2 6 13.5,
Table 2. Univariate Predictors of Nonculprit 90-min Flow (CTFC): Categorical Variables*
Present Absent p Value
Abnormal flow (CTFC $ 28) in culprit artery 33.5 6 16.1 (n 5 844) 27.8 6 13.0 (n 5 600) , 0.0001
TIMI grade 3 flow in culprit at 60 min 28.9 6 13.4 (n 5 335) 34.0 6 16.5 (n 5 412) , 0.0001
TIMI grade 3 flow in culprit at 75 min 28.6 6 13.0 (n 5 476) 34.1 6 16.2 (n 5 444) , 0.0001
TIMI grade 3 flow in culprit at 90 min 29.1 6 13.7 (n 5 1,050) 33.3 6 16.1 (n 5 752) , 0.0001
Culprit left anterior descending artery location 32.8 6 15.4 (n 5 820) 29.3 6 14.5 (n 5 997) , 0.0001
Culprit location ipsilateral to nonculprit location 32.2 6 14.3 (n 5 796) 29.8 6 15.4 (n 5 1,018) , 0.0001
Culprit receives collaterals from nonculprit artery 28.5 6 14.6 (n 5 280) 31.5 6 15.0 (n 5 1,442) 0.0001
Pulsatile flow in nonculprit artery 36.8 6 16.2 (n 5 248) 30.2 6 14.9 (n 5 1,333) , 0.0001
* Nonculprit CTFCs were ascertained at 90 min after thrombolysis. The following variables were validated as associated with the nonculprit CTFC in two separate random
cohorts: abnormal flow in culprit (p , 0.0001 for both); grade 3 flow in culprit at 60 min (p , 0.0001 and p 5 0.02); grade 3 flow in culprit at 75 min (p , 0.0001 and p 5
0.001); grade 3 flow in culprit at 90 min (p , 0.0001 for both); culprit LAD location (p , 0.0001 and p 5 0.001); and pulsatile flow in the nonculprit artery (p , 0.0001).
There was a trend towards validation for culprit arteries receiving collaterals from nonculprit arteries (p 5 0.0004 and p 5 0.07).
CTFC 5 corrected TIMI frame count.
Table 3. Univariate Predictors of Nonculprit 90-min Flow (CTFC): Continuous Variables*
Number of
Observations t Statistic
Correlation
Coefficient p Value
Culprit CTFC (frames) 1,444 8.2 0.21 , 0.0001
Culprit reference diameter (mm) 1,767 4.4 0.10 , 0.0001
Systolic blood pressure (mm Hg) 339 22.5 0.13 0.01
Mean arterial blood pressure (mm Hg) 248 22.1 0.13 0.04
Ventriculographic cardiac output (liters/min) 90 22.3 0.24 0.02
Double product 269 23.8 0.22 0.0002
Percent of culprit artery bed distal to stenosis
(including branches) (%)
49 2.1 0.29 0.04
Nonculprit minimum lumen diameter (mm) 223 22.6 0.17 0.01
Nonculprit percent diameter stenosis (%) 223 2.6 0.17 0.01
* All variables were ascertained at 90 min after thrombolysis. The following variables were validated as associated with nonculprit CTFC in two separate random cohorts: culprit
CTFC (p , 0.0001 in both cohorts); culprit reference diameter (p , 0.0001 and p 5 0.015); double product (p 5 0.01 and p 5 0.006); and nonculprit minimum lumen diameter
(p , 0.0001 in both cohorts). There was a tendency for the following variables to be valid in two separate random cohorts: systolic blood pressure (p 5 0.04 and p 5 0.152);
and nonculprit percent diameter stenosis (p 5 0.04 and p 5 0.146).
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n 5 254), but both were slower than normal (21 6 3.1
frames, p , 0.0005 for both).
Multivariable model for the 90-min CTFC in nonculprit
arteries. In a multivariate analysis, slower nonculprit artery
CTFCs were associated independently with slower culprit
artery CTFCs (p , 0.001), LAD culprit artery location
(p , 0.001), larger culprit artery reference segment diame-
ters (p 5 0.001) and a pulsatile flow pattern in the non-
culprit artery (p , 0.001). All variables remained indepen-
dent predictors when validated in two separate cohorts. In a
multivariable model restricted to arteries with hemodynamic
data available (n 5 226), slower nonculprit artery flow was
associated with a slower heart rate (p 5 0.002) and a lower
systolic blood pressure (p 5 0.002). When heart rate and
blood pressure were removed from the model (which are
used to calculate cardiac output and double product), it was
also associated with reduced ventriculographic cardiac out-
put (p 5 0.05) and a decreased double product (p 5 0.003)
in a multivariate model (n 5 89).
Role of hemodynamic perturbations in explaining slow
nonculprit artery flow in acute MI. To gain insight as to
whether perturbations in hemodynamics explained all of the
abnormalities in nonculprit artery flows, the CTFC in
patients with and without acute MI were compared in a
multivariable model that included both acute MI and
normal patients’ (n 5 102) hemodynamic data. In a multi-
variate analysis correcting for heart rate, systolic and dia-
stolic blood pressures, the nonculprit artery CTFC in the
setting of acute MI still remained 11.7 frames slower than
that in the absence of acute MI (p 5 0.0004).
Relationship between flow in all three arteries and
clinical outcomes. Given that flow was slowed globally,
the average CTFC of all three epicardial arteries at 90 min
after thrombolysis (the global CTFC) was analyzed to
determine if there was a relationship to adverse outcomes (a
composite adverse end point of in-hospital death, recurrent
MI, new shock or severe congestive heart failure [CHF], or
an ejection fraction [EF] ,40%) (Fig. 6). Patients who
remained event free had faster global CTFCs than patients
who experienced an adverse outcome (p 5 0.005). Likewise,
when the analysis was restricted to patients without a prior
MI, global CTFCs were faster in event-free patients than in
those who had an adverse outcome (p 5 0.009). When the
end points were examined individually, global flow was
slower in those patients who died (p 5 0.02), in those with
an EF ,40% (p 5 0.02) and in those with shock (p 5 0.03).
It tended to be slower in patients with death or recurrent MI
(p 5 0.054). Similar trends were seen when the analysis was
restricted to patients without a prior MI (p 5 0.06 for
death, p 5 0.07 for EF ,40%, p 5 0.01 for shock, p 5 0.05
for death or recurrent MI).
DISCUSSION
Relief of the coronary obstruction by thrombolysis or
percutaneous catheter-based intervention and restoration of
normal flow in the culprit artery has been the goal of therapy
in patients with acute MI. This analysis shows, however,
that acute MI slows flow not only in the culprit artery, but
also in the nonculprit artery by 45%. Culprit and nonculprit
artery flows were linked, and relief of the residual stenosis in
the culprit artery restored flow to the culprit artery, which
was the same as in the nonculprit arteries (both 30 frames).
Although improved post-PTCA, both culprit and noncul-
prit artery flows were still 45% slower than normal (21
frames). Multiple variables were associated with slower
nonculprit artery flow: slower flow in the associated culprit
artery, a larger territory infarcted (e.g., larger diameter
culprit arteries with a larger percent of the culprit vessel
distal to the stenosis, the absence of collaterals, LAD as the
culprit artery), tighter stenoses within the nonculprit artery,
the closer proximity or the ipsilateral location of the culprit
Table 4. Relationship Between Pulsatile Flow in Culprit Artery and Flow in Nonculprit Artery
Culprit With Continuous
Flow Pattern
Culprit With Pulsatile
Flow Pattern p Value
Percent of nonculprit arteries 13.2% 26.6% , 0.001
with pulsatile flow (%)† (354/2,683) (87/327)
CTFC of nonculprit arteries 30.9 6 15.0 33.5 6 15.9 0.01
(frames) (n 5 1,390) (n 5 190)
*All variables were ascertained at 90 min after thrombolysis. †The association was validated in two random cohorts of patients:
p , 0.001 for both data sets.
Figure 2. Relationship between culprit artery flow and nonculprit
artery flow for the LAD versus other locations. If the LAD was the
culprit artery, then nonculprit artery flow was slower by approxi-
mately 3.5 frames.
978 Gibson et al. JACC Vol. 34, No. 4, 1999
Impaired Nonculprit Artery Blood Flow in AMI October 1999:974–82
artery, lower systolic blood pressure, lower cardiac output
and a lower double product (an index of oxygen consump-
tion). Thus, acute MI slows flow globally, and this study
shows that slower global flow is associated with adverse
outcomes, including mortality.
It is also notable that slower nonculprit artery flow was
associated with the presence of regional wall motion abnor-
malities in the distribution of the nonculprit artery. Indeed,
Kramer et al. (16) have shown that five days after an acute
first MI in patients with single-vessel disease, there is
reduced circumferential shortening in remote noninfarcted
regions. It has been speculated that this may be due to either
reduced coronary vasodilation in remote territories (17), the
mechanical tethering of the remote region to the infarcted
region or changes in regional mechanical loads (16).
There was also concordance in culprit and nonculprit
territories in the development of systolic flow reversal, or the
no-reflow phenomenon. Recent Doppler velocity wire data
suggest that systolic retrograde flow reversal is more fre-
quently observed in the presence of the no-reflow phenom-
enon (17,18). The visual appreciation of grossly pulsatile
flow may be the angiographic analogue of these more
refined Doppler wire observations (17,18). Previous animal
laboratory studies have shown that focal areas of necrosis
Figure 3. Relationship between the presence of abnormal flow (CTFC $ 28) in nonculprit arteries and a wall motion abnormality within
the distribution of the nonculprit artery. Patients with abnormal nonculprit artery flow had a greater frequency of regional wall motion
abnormalities within the distribution of the nonculprit artery (p , 0.001). When the analysis was restricted to patients without a prior MI,
similar findings were observed (p 5 0.038).
Figure 4. Paired analysis of the change in the nonculprit artery CTFC over time. Flow improved by 1.4 frames between 60 and 75 min
(p 5 0.007, median 5 1), by 1.0 frame between 75 and 90 min (p 5 0.02, median 5 0.59) and by a total of 3.3 frames between 60 and
90 min after thrombolytic administration (p 5 0.0001, median 5 2).
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(micro-infarcts) occur in the nonoccluded (remote) poste-
rior segments of the left and right ventricles after occlusion
of the proximal LAD in dogs (19–23). It may be speculated
that delayed nonculprit artery flow may be the result of more
extensive necrosis in shared microvasculature, or occur as a
consequence of vasoconstriction, perhaps mediated by local
neurohumoral reflexes. Although we studied nonculprit
arteries that did not appear to lie in the direct distribution of
the culprit artery, these abnormalities in wall motion and
systolic flow reversal suggest that there may be shared
territories of injury.
Aside from protocol-mandated nitrate administration,
this study did not control for drug effect, and it is possible
that other drugs (e.g., beta blockers, calcium channel block-
ers, adenosine, sedatives) may have also modulated coronary
flow globally. Gregorini et al. have shown that PTCA and
stenting improve nonculprit artery flow from 53 to 42
frames (24), and stenting improves nonculprit flow from 40
to 25 frames (25). Infusion of the beta-adrenergic blocker
phentolamine further improved the nonculprit artery CTFC
to 19 frames and improved fractional shortening in noncul-
prit territories (24,25). We have also reported that in the
setting of acute coronary syndromes, PTCA accelerates flow
in the nonculprit artery in the RESTORE study (26). Thus,
neural mechanisms may be responsible in part for simulta-
neous inhibition of flow and left ventricular function in
remote regions.
Hemodynamic perturbations in the setting of acute MI
explain some, but do not appear to explain all, of the flow
delays in nonculprit arteries. The flow in patients with and
without acute MI were compared in a multivariable model
that included both acute MI and normal patients’ hemody-
namic data. Even when adjustments were made for the
hemodynamic abnormalities, nonculprit arteries in the acute
Figure 5. Relationship between improved nonculprit artery flow
and improved culprit artery flow between 60 and 90 min after
thrombolytic administration. When flow improved in the culprit
artery, flow in the associated nonculprit artery improved by 7.4
frames (p 5 0.0003), but when flow in the culprit artery did not
improve, there was no significant improvement in nonculprit artery
flow (1.0 frame, p 5 NS).
Figure 6. Relationship between the global CTFC (the average CTFC in all three arteries) and adverse outcomes. Patients who sustained
adverse events had slower global frame counts.
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MI setting were still slower than normal arteries in the
absence of MI by almost 11 frames, or nearly 50%.
In a recent article by French et al. (27), nonculprit artery
flow in the setting of acute MI (HERO-1 trial) was slowed
to 24 frames 90 min after thrombolytic administration
(median 20.9), lower than the 30.9 observed in this analysis.
Part of the reason for this difference may be due to the fact
that the French analysis only included patients with angio-
grams at both 90 min and 48 h (251 of 412 patients),
resulting in a potential selection bias towards patients
without an adverse event. It can be hypothesized that these
patients had better flow, as we demonstrated in this article,
and thus skewed the nonculprit CTFC lower. The HERO
study also used different antithrombotic agents and the
distribution of the infarct-related arteries may have also
been different (27).
Study limitations. The nonculprit artery CTFC could not
be ascertained in 6.4% of consecutive patients in the TIMI
10A, 10B and 14 trials (n 5 108/1,697 of patients with an
open nonculprit artery), and the culprit artery CTFC could
not be ascertained in 2.2% (n 5 30/1,341) of patients with
an open culprit artery. Hemodynamic data from the TIMI
4, 10A and 10B trials were not available, and the assessment
of the underlying effects of hemodynamic variables on
nonculprit arterial flow was conducted using data from the
TIMI 14 trial alone. Wall motion was assessed qualitatively,
and in most instances a single-plane projection (the right
anterior oblique) was used.
Recently, we demonstrated that when the force of injec-
tion is varied between the 10th and 90th percentile for
injection rates, the CTFC may change by approximately
two frames (28). Other groups have recently reported that
the TIMI Frame Counting method is very reproducible,
with a coefficient of correlation of .0.97 between observers,
and differences between observers of ,0.75 frames in the
study of French et al. (29,30). While the CTFC is a measure
of time, it does not account for vessel length or volume, and
it is therefore only an index of coronary flow and velocity.
More direct measurements of flow and velocity using other
methods, such as PET scanning, Doppler wires or magnetic
resonance imaging (MRI), are needed to further verify these
observations. Indeed, Doppler velocity wire studies and
PET studies have both confirmed that coronary flow reserve
is impaired in nonculprit arteries in the acute MI setting
(31,32).
Given the multiple variables that were analyzed in this
study, it is possible that some spurious results may have
emerged. However, many of the p values in this study are
below the 0.01 level, indicating that they are unlikely to be
spurious, and many of the variables were validated in two
random cohorts of patients (slower culprit artery CTFCs,
TIMI grade 3 flow in the culprit artery, LAD culprit artery
location, pulsatile flow, greater culprit artery reference
diameter, the nonculprit artery minimum diameter and the
double product), as was the multivariable model. Despite
the associations identified here, additional work is needed to
further understand the causes of abnormal nonculprit flow
on a more fundamental level. The association between
impaired global flow and outcomes does not definitively
prove that slower global flow causes adverse outcomes. It is
possible that slower global flow may be a marker for
impaired ventricular function or hemodynamic compromise.
It is unclear if slower global flow is a cause of or a result of
these associated ventricular function and hemodynamic
abnormalities.
Conclusions. Flow in nonculprit arteries is slowed by 45%
at 90 min after thrombolytic administration, and slower
nonculprit artery flow is linked to slower culprit artery flow.
Relief of the residual stenosis in the culprit artery restored
flow that was equal to that observed in the nonculprit artery,
but the resulting culprit artery flow was still slower than
normal. Acute MI reduces flow globally, and slower global
flow is associated with adverse clinical outcomes.
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